Rebecca Araujo

Rebecca Araujo is a contributing writer for DocWire News with experience covering the hematology/oncology specialty.

Articles by Rebecca Araujo

Rebecca AraujoChronic Myeloid Leukemia | September 23, 2024
Age ≥65 years, arrhythmia, and cardiogenic shock were associated with a significantly higher rate of acute heart failure.
Rebecca AraujoChronic Lymphocytic Leukemia | September 23, 2024
Liso-cel demonstrated clinical benefit and manageable safety, with low incidences of grade ≥3 CRS.
Rebecca AraujoAcute Myeloid Leukemia | September 23, 2024
Length of venetoclax dosing and prior chemotherapy exposure were associated with prolonged hematological recovery.
Rebecca AraujoAcute Lymphoblastic Leukemia | September 23, 2024
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
Rebecca AraujoAcute Myeloid Leukemia | September 18, 2024
The phase III SIERRA trial compared Iomab-B-led allogeneic HSCT with conventional care in older patients with AML.
Rebecca AraujoAcute Myeloid Leukemia | September 18, 2024
The prognostic significance of mNPM1 MRD is greatest in AML patients with concomitant FLT3-ITD.
Rebecca AraujoAcute Myeloid Leukemia | September 18, 2024
Some interventions such as PARP inhibitors can cause adverse events, but others such as HSCT can benefit patients.
Rebecca AraujoAcute Myeloid Leukemia | September 18, 2024
Sorafenib, a FLT3 inhibitor, led to significantly improved survival compared with placebo in patients with AML.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
An analysis of the PEGASUS and PRINCE clinical trials reported long-term efficacy of pegcetacoplan for patients with PNH.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
Imetelstat led to significant improvement of red blood cell-transfusion independence rates in patients with lower-risk MDS.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
Combination therapies involving PD-1 and CTLA-4 inhibitors exhibited promising activity and tolerability.
Rebecca AraujoMyelodysplastic Syndromes | September 5, 2024
Treatment with luspatercept led to significantly less healthcare resource utilization compared with ESAs.
Rebecca AraujoMyeloma | November 19, 2021
Researchers sought to calculate healthcare costs associated with triple class exposure to multiple myeloma.
Rebecca AraujoMantle Cell Lymphoma | February 1, 2023
Patients in the trial were treated for lymphoma, leukemia, or multiple myeloma.
Rebecca AraujoHodgkin Lymphoma | November 12, 2021
Older patients are at a significantly increased risk of immune-related AEs.
Rebecca AraujoMyeloma | November 14, 2022
A study published in Internal Medicine evaluated the safety profile of ixazomib in a cohort of Japanese patients with ...
Rebecca AraujoMyeloma | November 14, 2022
A study published in Environment International reported an elevated risk of multiple myeloma (MM) among female agricultural ...
Rebecca AraujoMyeloma | October 18, 2021
Researchers evaluated the effectiveness of a personalized sequential therapy for older patients with multiple myeloma.
Rebecca AraujoAcute Myeloid Leukemia | October 11, 2021
The researchers aimed to evaluate the incidence of patients eligible for non-intensive chemotherapy but receiving only BSC.
Rebecca AraujoAcute Lymphoblastic Leukemia | October 11, 2021
A study evaluated factors associated with intense end-of-life care among patients younger than 40 with blood cancer.